55382
当前位置: 首页   >  组员介绍   >  林心怡
林心怡 助理研究员    

林心怡工学博士,福建医科大学孟超肝胆医院助理研究员,福州市高层次D 类人才。主持福建省自然科学基金、福建省卫生计生科研人才培养项目、福州市科技计划项目等多个省部/厅局级项目,并作为核心成员参与国家级课题5项。以第一或通讯作者(含并列)在肿瘤免疫治疗、基因治疗及生物医用纳米材料等领域发表多篇SCI论文。

 

研究方向:肿瘤免疫治疗、新抗原疫苗、基因递送

 

代表性论著

1. Xinyi Lin#; Feida Li#; Jianhua Guan#; Xiaoyan Wang; Cuiping Yao; Yongyi Zeng*; Xiaolong Liu*; Janus silica nanoparticle-based tumor microenvironment modulator for restoring tumor sensitivity to programmed dell death ligand 1 immune checkpoint blockade therapy, ACS Nano, 2023, 17: 14494-14507.

2. Xinyi Lin#; Feida Li#; Qing Gu#; Xiaoyan Wang; Youshi Zheng; Jiong Li; Jianhua Guan; Cuiping Yao*; Xiaolong Liu*; Gold-seaurchin based immunomodulator enabling photothermal intervention and αCD16 transfection to boost NK cell adoptive immunotherapy, Acta Biomaterialia, 2022, 146: 406-420.

3. Xinyi Lin#; Xiaoyan Wang#; Jiong Li; Linsheng Cai; Fangyu Liao; Ming Wu; Dongye Zheng; Yongyi Zeng; Zhenxi Zhang; Xiaolong Liu; Jing Wang*; Cuiping Yao*; Localized NIR-II photoimmunotherapy through the combination of photothermal ablation and in situ generated interleukin12 cytokine for efficiently eliminating primary and abscopal tumors, Nanoscale, 2021, 13(3): 1745-1758.

4. Xiaoyan Wang; Ming Wu; Xiaolong Zhang; Feida Li; Yongyi Zeng; Xinyi Lin*; Xiaolong Liu*; Jingfeng Liu*; Hypoxia-responsive nanoreactors based on self-enhanced photodynamic sensitization and triggered ferroptosis for cancer synergistic therapy, Journal of Nanobiotechnology, 2021, 19: 204.

5. Xinyi Lin#; Ming Wu#; Ming Li; Zhixiong Cai; Haiyan Sun; Xionghong Tan; Jiong Li; Yongyi Zeng; Xiaolong Liu*; Jingfeng Liu*; Photo-responsive hollow silica nanoparticles for light-triggered genetic and photodynamic synergistic therapy, Acta Biomaterialia, 2018, 76: 178-192.

6. Ming Wu#; Xinyi Lin#; Xionghong Tan; Jiong Li; Zuwu Wei; Da Zhang; Youshi Zheng; Ai-xian Zheng; Bixing Zhao; Yongyi Zeng; Xiaolong Liu*; Jingfeng Liu*; Photoresponsive nanovehicle for two independent wavelength light-triggered sequential release of P-gp shRNA and doxorubicin to optimize and enhance synergistic therapy of multidrug-resistant cancer, ACS Applied Materials & Interfaces, 2018, 10(23): 19416-19427.